Toyserkani Navid Mohamadpour, Jensen Charlotte Harken, Andersen Ditte Caroline, Sheikh Søren Paludan, Sørensen Jens Ahm
Ann Plast Surg. 2018 Feb;80(2):181-187. doi: 10.1097/SAP.0000000000001184.
There is a rising interest in adipose-derived stromal cells for clinical use; however, it is unknown whether freshly isolated stromal cells (SVF) or culture-expanded cells (ASCs) are more efficacious. We therefore aimed to compare the 2 cellular therapies in an in vivo model of angiogenesis, the ischemic flap in rats, which induces acute ischemia. We also aimed to determine the importance of cell presence and the host immune response.
A total of 96 rats (n = 12 in each group) were used, and in each rat, a caudally based random flap measuring 2 × 7 cm was made. The study was conducted in 3 phases. First, each rat was treated with human SVF cells, human ASCs, or vehicle. Second, each rat was treated with human SVF, human SVF lysate, or vehicle. Finally, each rat was treated with rat (autologous) SVF cells or vehicle. Flap survival, vessel density, and stromal cell retention were evaluated after 7 days.
The mean survival rates for SVF treatment regardless of human or autologous origin were significantly increased as compared with the control group. Adipose stem/stromal cell and SVF lysate injection did not increase flap survival. Vessel density was increased for human and rat SVF and human ASC but not for SVF lysate. Human cells were not detected in the flaps after 7 days.
Flap survival increased with SVF treatment regardless of human or autologous origin, suggesting that increased flap survival is independent of the host immune response. All cell injections lead to increased vessel density, but it did not necessarily lead to increased flap survival. Further research should elaborate which molecular events make SVF treatment more efficacious than ASC.
脂肪来源的基质细胞在临床应用方面的关注度日益增加；然而，尚不清楚新鲜分离的基质细胞（SVF）还是培养扩增的细胞（ASC）更有效。因此，我们旨在通过血管生成的体内模型（大鼠缺血皮瓣，可诱导急性缺血）比较这两种细胞疗法。我们还旨在确定细胞存在的重要性以及宿主免疫反应。
总共使用了96只大鼠（每组n = 12只），在每只大鼠身上制作一个2×7厘米的尾侧随机皮瓣。研究分三个阶段进行。首先，每只大鼠接受人SVF细胞、人ASC或赋形剂治疗。其次，每只大鼠接受人SVF、人SVF裂解物或赋形剂治疗。最后，每只大鼠接受大鼠（自体）SVF细胞或赋形剂治疗。7天后评估皮瓣存活率、血管密度和基质细胞保留情况。
与对照组相比，无论人源还是自体来源的SVF治疗的平均存活率均显著提高。脂肪干/基质细胞和SVF裂解物注射并未提高皮瓣存活率。人源和大鼠源SVF以及人ASC的血管密度增加，但SVF裂解物未增加。7天后在皮瓣中未检测到人细胞。
无论人源还是自体来源，SVF治疗均可提高皮瓣存活率，这表明皮瓣存活率的提高与宿主免疫反应无关。所有细胞注射均导致血管密度增加，但不一定导致皮瓣存活率提高。进一步的研究应阐明哪些分子事件使SVF治疗比ASC更有效。
